Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows
The fear of testosterone and prostate cancer traces back to a single experiment in 1941, and understanding why that experiment convinced medicine for eight decades requires understanding what the experiment actually showed and what it did not.
Charles Huggins took men who had already been castrated and who already had advanced, metastatic prostate cancer, and he injected them with testosterone. Their cancer markers went up. He then showed that castrating men with prostate cancer caused those markers to fall. He won the Nobel Prize for this work, and the conclusion the medical community drew was simple: testosterone feeds prostate cancer, so adding it must be dangerous.
That conclusion is not entirely wrong. It is incomplete, and the incompleteness is where 80 years of fear came from.
The part that is correct is that prostate tissue does respond to testosterone, and in men who have essentially zero testosterone, like a castrated man, adding it back does stimulate prostate activity. That part is real. What the 1941 experiment could not tell you is whether that same relationship holds in men who already have normal testosterone levels, because all of Huggins' subjects were starting from near zero.
To understand why this distinction matters, you need a concept called the saturation model, which is the idea that the prostate's androgen receptors have a ceiling for how much testosterone they can actually respond to. Think of it like a sponge. A dry sponge absorbs water quickly and dramatically at first. But once it is saturated, pouring more water over it does nothing because it cannot hold any more. The prostate works the same way with testosterone.
Research published in 2009 by Morgentaler and Traish identified where that ceiling sits: around 240 to 250 nanograms per deciliter. Below that threshold, changes in testosterone produce large, measurable effects on prostate tissue. Above it, the response essentially plateaus. A healthy man with low normal testosterone of, say, 350 is already above that ceiling. A man with clinical hypogonadism at 200 might be near it. When you administer TRT and bring someone from 250 up to 600, you are not crossing a new threshold where the prostate suddenly has more fuel to burn. You are moving along the flat part of the curve where the receptors are already saturated.
This is the mechanism the 1941 study could not capture, because Huggins' subjects started at zero and moved through the steep part of the curve where the response is dramatic. The experiment was real. The extrapolation to normal men was the mistake.
What the modern studies show is consistent with this model. The largest randomized controlled trial on this question followed 5,204 men for 33 months, comparing TRT directly against placebo, and the prostate cancer rate was 0.46 percent in the TRT group against 0.42 percent in the placebo group, which produced a hazard ratio of 1.07 and a p-value of 0.87. That is not a statistically meaningful difference. That is noise.
A Finnish population study following 78,615 men over 18 years found something even more striking: prostate cancer specific mortality was actually lower in TRT users, with a hazard ratio of 0.52. That does not mean testosterone protects against prostate cancer, and it would be a mistake to overclaim in that direction, but it does mean that the men using TRT were not dying of prostate cancer at higher rates. They were dying at lower rates, which is the opposite of what the 1941 logic would predict.
A 2024 meta-analysis pooling 28 randomized controlled trials measured what happens to PSA, which is something called prostate-specific antigen and is a blood marker that reflects prostate cell activity, over the course of TRT. The average change across all those trials was 0.08 nanograms per milliliter. For context, a clinically meaningful PSA shift is generally considered to be above 1.4. A change of 0.08 is the kind of number that sits inside normal daily variation. The same meta-analysis found that urinary symptom scores changed by exactly zero.
The most direct test of the old theory, though, is what happens when you give testosterone to men who already have prostate cancer. If testosterone truly caused or fed prostate cancer the way Huggins' experiment implied, giving it to men with a history of treated prostate cancer should cause recurrence. A study of 69,984 men who had received definitive treatment for localized prostate cancer identified 1,012 of them who subsequently used TRT and followed them forward. There was no increase in recurrence and no increase in death. If existing prostate cancer does not wake back up when testosterone is added, the argument that testosterone creates prostate cancer in healthy men has no biological footing left to stand on.
None of this means you ignore your prostate entirely when starting TRT. The Endocrine Society's clinical practice guideline recommends getting a baseline PSA before starting, checking it again at three to six months, and then monitoring it annually after that. The threshold that should prompt a urology referral is a rise of more than 1.4 nanograms per milliliter above your baseline, not a single number in isolation, but a meaningful jump from where you started.
That protocol exists not because TRT causes cancer, but because TRT is typically started in middle-aged men, who are the same population where prostate cancer naturally starts to appear regardless of anything they are doing, and you want to catch something that was already developing rather than mistake it for a treatment effect.
The reason this history matters is that medicine inherited a conclusion from an experiment that was never designed to answer the question it was used to answer. Huggins showed what happens when you go from zero testosterone to some testosterone in men with advanced cancer. Medicine heard "testosterone causes prostate cancer" and that belief sat largely unchallenged for decades because no one was running the studies that would have corrected it. The studies that finally ran the experiment properly found no signal.
An 80-year-old fear built on one incomplete experiment is still shaping decisions men make today, and that is the actual story.
References
- Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
- Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
- Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
- Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
- Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
- Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
- Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.